| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,682 |
8,783 |
$2.01M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,821 |
7,249 |
$1.32M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,190 |
4,726 |
$1.30M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,196 |
1,127 |
$414K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,123 |
1,846 |
$304K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,703 |
1,593 |
$155K |
| 71046 |
Radiologic examination, chest; 2 views |
3,053 |
2,844 |
$143K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,104 |
4,579 |
$140K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
3,108 |
2,736 |
$133K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,014 |
4,033 |
$128K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,230 |
1,184 |
$118K |
| 80053 |
Comprehensive metabolic panel |
12,041 |
9,805 |
$96K |
| 71045 |
Radiologic examination, chest; single view |
3,674 |
2,485 |
$90K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
852 |
816 |
$77K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
14,616 |
10,650 |
$73K |
| G0378 |
Hospital observation service, per hour |
1,301 |
579 |
$70K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
1,377 |
1,227 |
$65K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
964 |
888 |
$63K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
552 |
518 |
$63K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,532 |
2,991 |
$57K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,227 |
967 |
$56K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
908 |
686 |
$56K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,231 |
1,140 |
$52K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,053 |
2,418 |
$49K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
438 |
406 |
$46K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
291 |
260 |
$45K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
844 |
748 |
$44K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
663 |
600 |
$39K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,806 |
3,286 |
$35K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,678 |
464 |
$34K |
| 84484 |
|
3,728 |
2,811 |
$31K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
359 |
340 |
$29K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,910 |
1,732 |
$27K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,214 |
2,839 |
$26K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,997 |
1,686 |
$23K |
| 81025 |
|
3,137 |
2,938 |
$19K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,785 |
2,565 |
$17K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
86 |
75 |
$17K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,277 |
1,164 |
$15K |
| 83690 |
|
2,700 |
2,458 |
$14K |
| 83880 |
|
717 |
575 |
$13K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
116 |
116 |
$13K |
| 76801 |
|
144 |
122 |
$12K |
| 81001 |
|
5,175 |
4,677 |
$12K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
621 |
562 |
$12K |
| 80061 |
Lipid panel |
1,527 |
1,307 |
$12K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,709 |
1,468 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
675 |
430 |
$11K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,189 |
1,045 |
$11K |
| 36415 |
Collection of venous blood by venipuncture |
3,467 |
2,734 |
$9K |
| 86901 |
|
1,196 |
1,059 |
$9K |
| 85027 |
|
2,670 |
1,661 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
159 |
153 |
$8K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
300 |
224 |
$6K |
| 84703 |
|
1,126 |
1,049 |
$6K |
| 83735 |
|
1,971 |
1,042 |
$5K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
53 |
52 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
284 |
277 |
$5K |
| 84702 |
|
810 |
699 |
$5K |
| 87400 |
|
158 |
142 |
$5K |
| 81003 |
|
2,544 |
2,333 |
$4K |
| 93975 |
|
60 |
55 |
$4K |
| 87077 |
|
657 |
595 |
$4K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,222 |
1,789 |
$4K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
16 |
15 |
$4K |
| 82247 |
|
1,187 |
698 |
$4K |
| 86900 |
|
1,174 |
1,042 |
$4K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,765 |
1,383 |
$4K |
| 85610 |
|
1,724 |
1,350 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
1,828 |
1,571 |
$4K |
| 87186 |
|
548 |
494 |
$4K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
149 |
141 |
$3K |
| 85730 |
|
1,127 |
874 |
$3K |
| 82248 |
|
946 |
549 |
$3K |
| 99152 |
|
41 |
36 |
$3K |
| 73562 |
|
58 |
51 |
$3K |
| 73030 |
|
48 |
45 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
149 |
141 |
$3K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,683 |
2,183 |
$3K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
828 |
213 |
$3K |
| 80320 |
|
244 |
213 |
$2K |
| 83605 |
|
423 |
293 |
$2K |
| 82962 |
|
828 |
221 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,309 |
2,880 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,652 |
2,377 |
$2K |
| 86850 |
|
241 |
215 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,668 |
3,902 |
$2K |
| 87081 |
|
223 |
194 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
121 |
100 |
$2K |
| 96376 |
|
119 |
88 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
173 |
161 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
923 |
782 |
$2K |
| 73610 |
|
27 |
25 |
$2K |
| 71250 |
|
13 |
12 |
$1K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
44 |
44 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
819 |
685 |
$1K |
| 85379 |
|
240 |
179 |
$1K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
15 |
12 |
$1K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
16 |
15 |
$1K |
| 73630 |
|
25 |
24 |
$1K |
| 74018 |
|
14 |
13 |
$976.43 |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
12 |
12 |
$906.91 |
| 93971 |
|
13 |
13 |
$896.24 |
| Q3014 |
Telehealth originating site facility fee |
92 |
88 |
$886.36 |
| 73560 |
|
41 |
38 |
$858.78 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
998 |
692 |
$840.45 |
| 82607 |
|
80 |
67 |
$821.31 |
| 72100 |
|
27 |
26 |
$809.49 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
13 |
12 |
$799.73 |
| 87040 |
|
92 |
69 |
$692.18 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,138 |
942 |
$657.07 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
104 |
25 |
$607.81 |
| APT02 |
|
81 |
43 |
$575.10 |
| 82570 |
|
98 |
78 |
$462.87 |
| 86803 |
|
53 |
44 |
$451.01 |
| 87088 |
|
70 |
61 |
$435.61 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
59 |
56 |
$425.24 |
| J3490 |
Unclassified drugs |
292 |
217 |
$371.12 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,788 |
1,544 |
$369.97 |
| 80330 |
|
19 |
16 |
$358.48 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
254 |
177 |
$357.04 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
15 |
14 |
$346.76 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
28 |
24 |
$336.74 |
| 80076 |
|
73 |
65 |
$334.28 |
| 82728 |
|
26 |
24 |
$296.22 |
| 82565 |
|
124 |
120 |
$293.80 |
| 86140 |
|
68 |
61 |
$291.22 |
| 72170 |
|
12 |
12 |
$280.89 |
| 84439 |
|
48 |
42 |
$280.74 |
| 36416 |
|
280 |
205 |
$244.78 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
144 |
126 |
$188.41 |
| 83655 |
|
13 |
12 |
$187.90 |
| APT17 |
|
12 |
12 |
$178.44 |
| A9270 |
Non-covered item or service |
3,696 |
1,127 |
$164.50 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
22 |
19 |
$160.90 |
| 82550 |
|
50 |
40 |
$159.88 |
| 82746 |
|
16 |
12 |
$153.75 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
66 |
53 |
$106.89 |
| 80305 |
|
14 |
13 |
$99.04 |
| 83550 |
|
13 |
12 |
$88.08 |
| J2060 |
Injection, lorazepam, 2 mg |
116 |
78 |
$83.92 |
| 83540 |
|
13 |
12 |
$69.90 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
47 |
42 |
$68.49 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
81 |
57 |
$65.60 |
| 84145 |
|
27 |
13 |
$57.06 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
93 |
89 |
$44.71 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
35 |
30 |
$40.05 |
| 85018 |
|
13 |
12 |
$33.84 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
301 |
271 |
$26.11 |
| C9113 |
Injection, pantoprazole sodium, per vial |
21 |
12 |
$14.82 |
| J7050 |
Infusion, normal saline solution, 250 cc |
46 |
34 |
$14.06 |
| J1644 |
Injection, heparin sodium, per 1000 units |
76 |
25 |
$10.33 |
| 80329 |
|
19 |
15 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
15 |
12 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
15 |
12 |
$0.00 |